These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study. Vannucchi G; Covelli D; Campi I; Currò N; Dazzi D; Rodari M; Pepe G; Chiti A; Guastella C; Lazzaroni E; Salvi M Thyroid; 2019 Dec; 29(12):1828-1833. PubMed ID: 31860407 [No Abstract] [Full Text] [Related]
4. Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature. Batra R; Krishnasamy SK; Buch H; Sandramouli S Semin Ophthalmol; 2015 May; 30(3):227-31. PubMed ID: 24409943 [TBL] [Abstract][Full Text] [Related]
5. Radioactive iodine therapy for pediatric Graves' disease: a single-center experience over a 10-year period. Kaplowitz PB; Jiang J; Vaidyanathan P J Pediatr Endocrinol Metab; 2020 Mar; 33(3):383-389. PubMed ID: 31603857 [TBL] [Abstract][Full Text] [Related]
6. The tale of radioiodine and Graves' orbitopathy. Ponto KA; Zang S; Kahaly GJ Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895 [TBL] [Abstract][Full Text] [Related]
7. Radioactive iodine (RAI) treatment of hyperthyroidism is safe in patients with Graves' orbitopathy--a prospective study. Król A; Koehler A; Nowak M; Paliczka-Cieślik E; Krajewska J; Kalemba M; Jurecka-Lubieniecka B; Hasse-Lazar K; Michalik B; Szpak-Ulczok S; Zarudzki Ł; Roskosz J; Jarząb B Endokrynol Pol; 2014; 65(1):40-5. PubMed ID: 24549601 [TBL] [Abstract][Full Text] [Related]
8. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. Kung AW; Yau CC; Cheng A J Clin Endocrinol Metab; 1994 Aug; 79(2):542-6. PubMed ID: 7913934 [TBL] [Abstract][Full Text] [Related]
9. Radioactive iodine treatment for Graves' hyperthyroidism: incidence of Graves orbitopathy. Quah NQX; Sobti MM; Wren AM; Scawn R; Kalogianni E; Cleland J; Maenhout A Nucl Med Commun; 2024 Feb; 45(2):103-107. PubMed ID: 37982569 [TBL] [Abstract][Full Text] [Related]
10. Transient Hypothyroidism after Radioiodine for Graves' Disease: Challenges in Interpreting Thyroid Function Tests. Sheehan MT; Doi SA Clin Med Res; 2016 Mar; 14(1):40-5. PubMed ID: 26864507 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of radioiodine therapy for mild Graves ophthalmopathy depending on cigarette consumption: a 6‑month follow‑up. Czarnywojtek A; Komar-Rychlicka K; Zgorzalewicz-Stachowiak M; Sawicka-Gutaj N; Woliński K; Gut P; Płazinska M; Torlińska B; Florek E; Waligórska-Stachura J; Ruchała M Pol Arch Med Wewn; 2016 Aug; 126(10):746-753. PubMed ID: 27534827 [TBL] [Abstract][Full Text] [Related]
12. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study. Lai A; Sassi L; Compri E; Marino F; Sivelli P; Piantanida E; Tanda ML; Bartalena L J Clin Endocrinol Metab; 2010 Mar; 95(3):1333-7. PubMed ID: 20061414 [TBL] [Abstract][Full Text] [Related]
13. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. Tallstedt L; Lundell G; Tørring O; Wallin G; Ljunggren JG; Blomgren H; Taube A N Engl J Med; 1992 Jun; 326(26):1733-8. PubMed ID: 1489388 [TBL] [Abstract][Full Text] [Related]
14. Treating the thyroid in the presence of Graves' ophthalmopathy. Hegedüs L; Bonnema SJ; Smith TJ; Brix TH Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):313-24. PubMed ID: 22632368 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant lithium improves the efficacy of radioactive iodine treatment in Graves' and toxic nodular disease. Martin NM; Patel M; Nijher GM; Misra S; Murphy E; Meeran K Clin Endocrinol (Oxf); 2012 Oct; 77(4):621-7. PubMed ID: 22443227 [TBL] [Abstract][Full Text] [Related]
16. Redistribution of body composition in patients with Graves' disease after iodine-131 treatment. Xie LJ; Zhou HJ; Li JF; Zhang F; Zeng FW; Qin LP; Chen Y; Yuan HJ; Cheng MH Eur J Clin Nutr; 2015 Jul; 69(7):856-61. PubMed ID: 25351654 [TBL] [Abstract][Full Text] [Related]
17. What influences early hypothyroidism after radioiodine treatment for Graves' hyperthyroidism? Vijayakumar V; Ali S; Nishino T; Nusynowitz M Clin Nucl Med; 2006 Nov; 31(11):688-9. PubMed ID: 17053385 [TBL] [Abstract][Full Text] [Related]
18. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. Bogazzi F; Giovannetti C; Fessehatsion R; Tanda ML; Campomori A; Compri E; Rossi G; Ceccarelli C; Vitti P; Pinchera A; Bartalena L; Martino E J Clin Endocrinol Metab; 2010 Jan; 95(1):201-8. PubMed ID: 19906789 [TBL] [Abstract][Full Text] [Related]
19. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study. De Bellis A; Conzo G; Cennamo G; Pane E; Bellastella G; Colella C; Iacovo AD; Paglionico VA; Sinisi AA; Wall JR; Bizzarro A; Bellastella A Endocrine; 2012 Apr; 41(2):320-6. PubMed ID: 22169963 [TBL] [Abstract][Full Text] [Related]
20. Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. Vannucchi G; Campi I; Covelli D; Dazzi D; Currò N; Simonetta S; Ratiglia R; Beck-Peccoz P; Salvi M J Clin Endocrinol Metab; 2009 Sep; 94(9):3381-6. PubMed ID: 19567525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]